{"title":"2型糖尿病:新药，新视角","authors":"A. Goldfine","doi":"10.1080/21548331.2001.11444143","DOIUrl":null,"url":null,"abstract":"Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitizers.","PeriodicalId":75913,"journal":{"name":"Hospital practice","volume":"36 1","pages":"29 - 36"},"PeriodicalIF":0.0000,"publicationDate":"2001-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21548331.2001.11444143","citationCount":"9","resultStr":"{\"title\":\"Type 2 Diabetes: New Drugs, New Perspectives\",\"authors\":\"A. Goldfine\",\"doi\":\"10.1080/21548331.2001.11444143\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitizers.\",\"PeriodicalId\":75913,\"journal\":{\"name\":\"Hospital practice\",\"volume\":\"36 1\",\"pages\":\"29 - 36\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2001-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21548331.2001.11444143\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21548331.2001.11444143\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21548331.2001.11444143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitizers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
